37 Alzheimer’s Disease
Amspoker, A. B., Hersch, G., Snow, A. L., Wilson, N., Morgan, R. O., Sansgiry, S., & Kunik, M. E. (2019). A psychometric evaluation of the pleasant events schedule–alzheimer’s disease (short version): Among a veteran population. Journal of Applied Gerontology, 38(5), 673–693. https://doi.org/10.1177/0733464817690675
Iacono, D., Lee, P., Edlow, B. L., Gray, N., Fischl, B., Kenney, K., Lew, H. L., Lozanoff, S., Liacouras, P., Lichtenberger, J., Dams-O’Connor, K., Cifu, D., Hinds, S. R., & Perl, D. P. (2020). Early-onset dementia in war veterans: Brain polypathology and clinicopathologic complexity. Journal of Neuropathology & Experimental Neurology, 79(2), 144–162. https://doi.org/10.1093/jnen/nlz122
Karran, M., Guerrero-Berroa, E., Schmeidler, J., Lee, P. G., Alexander, N., Nabozny, M., West, R. K., Beeri, M. S., Sano, M., & Silverman, J. M. (2019). Recruitment of older veterans with diabetes risk for Alzheimer’s Disease for a randomized clinical trial of computerized cognitive training. Journal of Alzheimer’s Disease, 69(2), 401–411. https://doi.org/10.3233/JAD-180952
Kempuraj, D., Ahmed, M. E., Selvakumar, G. P., Thangavel, R., Raikwar, S. P., Zaheer, S. A., Iyer, S. S., Burton, C., James, D., & Zaheer, A. (2020). Psychological stress–induced immune response and risk of Alzheimer’s disease in veterans from Operation Enduring Freedom and Operation Iraqi Freedom. Clinical Therapeutics, 42(6), 974–982. https://doi.org/10.1016/j.clinthera.2020.02.018
Stuve, O., Weideman, R. A., McMahan, D. M., Jacob, D. A., & Little, B. B. (2020). Diclofenac reduces the risk of Alzheimer’s disease: A pilot analysis of NSAIDs in two US veteran populations. Therapeutic Advances in Neurological Disorders, 13, https://doi.org/10.1177/1756286420935676